High Growth Tech Stocks In Europe For July 2025

HLSE:QTCOM Revenue and Expenses Breakdown as at Jul 2025

Simply Wall St Growth Rating: ★★★★★☆

Overview: BioGaia AB (publ) is a healthcare company that develops, manufactures, markets, and sells probiotic products for gut, oral, and immune health across multiple regions including Europe and the Asia-Pacific, with a market cap of SEK10.42 billion.

Operations: The company’s primary revenue streams include Pediatrics, generating SEK1.08 billion, and Adult Health, contributing SEK352.62 million. BioGaia operates across diverse global markets such as Europe, the Middle East, Africa, the United States, and the Asia-Pacific region.

BioGaia is navigating a transformative phase, marked by its recent expansion into the burgeoning skin microbiome market through its subsidiary, BioGaia New Sciences AB. This move taps into a sector poised for rapid growth, with the global skin microbiome market expected to expand from $1.03 billion in 2024 to $2.86 billion by 2032 at a CAGR of 13.7%. Despite facing challenges such as a year-over-year earnings decline of 28.6%, BioGaia’s strategic diversification could harness long-term benefits, supported by an anticipated annual revenue growth of 11.1% and earnings growth forecast at 22.3%. This strategy not only broadens BioGaia’s product offerings but also aligns with evolving consumer preferences towards science-backed health solutions, positioning it well within the high-growth trajectory of tech-enabled biotech sectors.

OM:BIOG B Revenue and Expenses Breakdown as at Jul 2025

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Ependion AB, with a market cap of approximately SEK3.89 billion, offers digital solutions for secure control, management, visualization, and data communication tailored for industrial applications through its subsidiaries.

Operations: Ependion AB generates revenue primarily through its subsidiaries Westermo and Beijer Electronics, including Korenix, with contributions of SEK1.29 billion and SEK890.26 million, respectively.

Ependion AB, amid a challenging market backdrop with a recent sales dip to SEK 560.76 million from SEK 588.36 million year-over-year, still demonstrates robust future potential with forecasted earnings growth of 35.3% annually, outpacing the Swedish market’s average of 16.9%. Despite a temporary setback in net income dropping to SEK 30.28 million from SEK 39.77 million, the company’s commitment to innovation is evident in its R&D investments and strategic shifts like the follow-on equity offering raising SEK 300 million, positioning it well for rebound and growth in the tech sector.

OM:EPEN Earnings and Revenue Growth as at Jul 2025

Access the full spectrum of 51 European High Growth Tech and AI Stocks by clicking on this link.

Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St’s portfolio, where intuitive tools await to help optimize your investment outcomes.

Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include HLSE:QTCOM OM:BIOG B and OM:EPEN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com